Terry Hermiston

Terry Hermiston is an accomplished biopharmaceutical executive with extensive experience in developing innovative treatments, particularly in the fields of hematology and immuno-oncology. As the CEO and Founder of Coagulant Therapeutics, Inc. since January 2017, Terry aims to create the first approved pharmaceutical treatment for acute bleeding, leveraging FVIIa assets acquired from Bayer HealthCare. Additionally, as the CEO and Founder of GLAdiator Biosciences since August 2018, Terry leads efforts in biologics targeting cancer cells. Previously, Terry served as VP and Head of Biologics Research at Bayer, where significant contributions were made to biologics development and research management. Other notable roles include board membership at Jennerex Biotherapeutics and participation in scientific advisory boards for various biotechnology companies. Terry earned a Ph.D. in Virology from Iowa State University and a bachelor's degree in Microbiology from the University of Iowa.